Eli Lilly Stock Rises as Firm Plans to Ask for Weight-Loss Pill Approval

Eli Lilly (LLY) shares gained more than 4% soon after the opening bell Tuesday as results from a new study moved the drugmaker closer to applying for approval of its experimental weight-loss pill.

Lilly reported a Phase 3 trial of its oral GLP-1 treatment, orforglipron, met primary and key secondary goals in reducing weight for adults who were obese or overweight and had Type 2 diabetes. 

The company noted those taking the highest dose (36 milligrams) for 72 weeks and without food and water restrictions dropped their weight by an average of 10.5%, or 22.9 pounds, compared to 2.2%, or 5.1 pounds, for those on a placebo. Along with losing weight, the orforglipron patients had an average decline in their A1C glucose level of 1.8%. 

The pill uses the same GLP-1 hormone therapy as injectable weight-loss medicines, including Lilly’s Zepbound and Novo Nordisk’s (NVO) Wegovy. However, the size of orforglipron’s weight reduction was lower than the other two. 

Lilly said it now has “the full clinical data package required to initiate global regulatory submissions for orforglipron.” However, a stumbling block may be the high number of adverse effects reported, including nausea (36.4% at the highest dosage), vomiting (23.1%), diarrhea (27.4%), constipation (22.4%), and dyspepsia (10.9%). In addition, a similar number of those taking the pill and the placebo dropped out of the study. 

Despite today’s advance, shares of Eli Lilly are down about 6% in 2025.